Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

Dai Chihara, Yasuhiro Oki, Michelle A. Fanale, Jason R. Westin, Loretta J. Nastoupil, Sattva Neelapu, Luis Fayad, Nathan H. Fowler, Chan Yoon Cheah

Research output: Contribution to journalArticle

Abstract

Stage I non-Hodgkin lymphoma (NHL) is rare; prognostic impact of different histologic subtypes and treatment modality is still unclear. We used the Surveillance, Epidemiology and End Results (SEER) database to evaluate survival outcomes among adult patients (age >= 18 years, N = 58,230) diagnosed with stage I NHL of various histologic subtypes between 1998 and 2014. Five-year disease-specific survival of patients with stage I diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and peripheral T cell lymphoma (PTCL) was 82%, 92%, 95%, 89%, 78%, 77%, and 77%, respectively. The median disease-specific survival was not reached in all histologic subtypes analyzed; however, there does not appear to be a plateau in disease-specific survival of patients with stage I NHL irrespective of subtypes. Although lymphoma was the most common cause of death (40.7%), death from other cancer (17.4%) and cardiovascular disease (13.6%) were also frequent. Chemotherapy appeared favorably associated with OS in patients with DLBCL, BL, and MCL while patients with FL, MZL, SLL, and PTCL who require chemotherapy for initial treatment showed shorter OS. Patients with stage I NHL have favorable disease-specific survival; however, no plateau was seen regardless of histologic subtypes thus suggesting that patients may need attention and follow-up even in aggressive lymphomas after 5 years of remission.

Original languageEnglish
Pages (from-to)1169-1176
Number of pages8
JournalAnnals of Hematology
Volume98
Issue number5
DOIs
Publication statusPublished - May 2019

Cite this

Chihara, D., Oki, Y., Fanale, M. A., Westin, J. R., Nastoupil, L. J., Neelapu, S., ... Cheah, C. Y. (2019). Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? Annals of Hematology, 98(5), 1169-1176. https://doi.org/10.1007/s00277-018-3571-7
Chihara, Dai ; Oki, Yasuhiro ; Fanale, Michelle A. ; Westin, Jason R. ; Nastoupil, Loretta J. ; Neelapu, Sattva ; Fayad, Luis ; Fowler, Nathan H. ; Cheah, Chan Yoon. / Stage I non-Hodgkin lymphoma : no plateau in disease-specific survival ?. In: Annals of Hematology. 2019 ; Vol. 98, No. 5. pp. 1169-1176.
@article{a144b48071e548ac872a21a6b6900929,
title = "Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?",
abstract = "Stage I non-Hodgkin lymphoma (NHL) is rare; prognostic impact of different histologic subtypes and treatment modality is still unclear. We used the Surveillance, Epidemiology and End Results (SEER) database to evaluate survival outcomes among adult patients (age >= 18 years, N = 58,230) diagnosed with stage I NHL of various histologic subtypes between 1998 and 2014. Five-year disease-specific survival of patients with stage I diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and peripheral T cell lymphoma (PTCL) was 82{\%}, 92{\%}, 95{\%}, 89{\%}, 78{\%}, 77{\%}, and 77{\%}, respectively. The median disease-specific survival was not reached in all histologic subtypes analyzed; however, there does not appear to be a plateau in disease-specific survival of patients with stage I NHL irrespective of subtypes. Although lymphoma was the most common cause of death (40.7{\%}), death from other cancer (17.4{\%}) and cardiovascular disease (13.6{\%}) were also frequent. Chemotherapy appeared favorably associated with OS in patients with DLBCL, BL, and MCL while patients with FL, MZL, SLL, and PTCL who require chemotherapy for initial treatment showed shorter OS. Patients with stage I NHL have favorable disease-specific survival; however, no plateau was seen regardless of histologic subtypes thus suggesting that patients may need attention and follow-up even in aggressive lymphomas after 5 years of remission.",
keywords = "Stage I lymphoma, Disease-specific survival, SEER, Radiation, B-CELL LYMPHOMA, RADIOTHERAPY, CHEMOTHERAPY, IRRADIATION, CHOP",
author = "Dai Chihara and Yasuhiro Oki and Fanale, {Michelle A.} and Westin, {Jason R.} and Nastoupil, {Loretta J.} and Sattva Neelapu and Luis Fayad and Fowler, {Nathan H.} and Cheah, {Chan Yoon}",
year = "2019",
month = "5",
doi = "10.1007/s00277-018-3571-7",
language = "English",
volume = "98",
pages = "1169--1176",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer",
number = "5",

}

Chihara, D, Oki, Y, Fanale, MA, Westin, JR, Nastoupil, LJ, Neelapu, S, Fayad, L, Fowler, NH & Cheah, CY 2019, 'Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?' Annals of Hematology, vol. 98, no. 5, pp. 1169-1176. https://doi.org/10.1007/s00277-018-3571-7

Stage I non-Hodgkin lymphoma : no plateau in disease-specific survival ? / Chihara, Dai; Oki, Yasuhiro; Fanale, Michelle A.; Westin, Jason R.; Nastoupil, Loretta J.; Neelapu, Sattva; Fayad, Luis; Fowler, Nathan H.; Cheah, Chan Yoon.

In: Annals of Hematology, Vol. 98, No. 5, 05.2019, p. 1169-1176.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Stage I non-Hodgkin lymphoma

T2 - no plateau in disease-specific survival ?

AU - Chihara, Dai

AU - Oki, Yasuhiro

AU - Fanale, Michelle A.

AU - Westin, Jason R.

AU - Nastoupil, Loretta J.

AU - Neelapu, Sattva

AU - Fayad, Luis

AU - Fowler, Nathan H.

AU - Cheah, Chan Yoon

PY - 2019/5

Y1 - 2019/5

N2 - Stage I non-Hodgkin lymphoma (NHL) is rare; prognostic impact of different histologic subtypes and treatment modality is still unclear. We used the Surveillance, Epidemiology and End Results (SEER) database to evaluate survival outcomes among adult patients (age >= 18 years, N = 58,230) diagnosed with stage I NHL of various histologic subtypes between 1998 and 2014. Five-year disease-specific survival of patients with stage I diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and peripheral T cell lymphoma (PTCL) was 82%, 92%, 95%, 89%, 78%, 77%, and 77%, respectively. The median disease-specific survival was not reached in all histologic subtypes analyzed; however, there does not appear to be a plateau in disease-specific survival of patients with stage I NHL irrespective of subtypes. Although lymphoma was the most common cause of death (40.7%), death from other cancer (17.4%) and cardiovascular disease (13.6%) were also frequent. Chemotherapy appeared favorably associated with OS in patients with DLBCL, BL, and MCL while patients with FL, MZL, SLL, and PTCL who require chemotherapy for initial treatment showed shorter OS. Patients with stage I NHL have favorable disease-specific survival; however, no plateau was seen regardless of histologic subtypes thus suggesting that patients may need attention and follow-up even in aggressive lymphomas after 5 years of remission.

AB - Stage I non-Hodgkin lymphoma (NHL) is rare; prognostic impact of different histologic subtypes and treatment modality is still unclear. We used the Surveillance, Epidemiology and End Results (SEER) database to evaluate survival outcomes among adult patients (age >= 18 years, N = 58,230) diagnosed with stage I NHL of various histologic subtypes between 1998 and 2014. Five-year disease-specific survival of patients with stage I diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and peripheral T cell lymphoma (PTCL) was 82%, 92%, 95%, 89%, 78%, 77%, and 77%, respectively. The median disease-specific survival was not reached in all histologic subtypes analyzed; however, there does not appear to be a plateau in disease-specific survival of patients with stage I NHL irrespective of subtypes. Although lymphoma was the most common cause of death (40.7%), death from other cancer (17.4%) and cardiovascular disease (13.6%) were also frequent. Chemotherapy appeared favorably associated with OS in patients with DLBCL, BL, and MCL while patients with FL, MZL, SLL, and PTCL who require chemotherapy for initial treatment showed shorter OS. Patients with stage I NHL have favorable disease-specific survival; however, no plateau was seen regardless of histologic subtypes thus suggesting that patients may need attention and follow-up even in aggressive lymphomas after 5 years of remission.

KW - Stage I lymphoma

KW - Disease-specific survival

KW - SEER

KW - Radiation

KW - B-CELL LYMPHOMA

KW - RADIOTHERAPY

KW - CHEMOTHERAPY

KW - IRRADIATION

KW - CHOP

U2 - 10.1007/s00277-018-3571-7

DO - 10.1007/s00277-018-3571-7

M3 - Article

VL - 98

SP - 1169

EP - 1176

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -

Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S et al. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? Annals of Hematology. 2019 May;98(5):1169-1176. https://doi.org/10.1007/s00277-018-3571-7